OXA1L and cancer: The cisplatin gene signature Cis1 performed best on stage IV patients (overall accuracy of 72.4% at a 2-year recurrence threshold), while Oxa1 similarly performed best in predicting late stage cancers (74.5% accurate for stage III and 71.4% accurate for stage IV at a 2-year recurrence threshold).